Crescita Therapeutics Inc. is a dermatology-focused enterprise that offers a comprehensive portfolio of both over-the-counter skincare products and prescription medications, distributed across Canada, the United States, and other international markets. The company operates through three principal divisions: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. Central to its innovation are proprietary platform technologies, MMPE and DuraPeel, which are specifically employed in the formulation of topical treatments containing cannabis and hemp compounds. Crescita's prescription drug lineup includes Pliaglis, a topical local anesthetic cream designed to provide dermal analgesia on intact skin prior to superficial dermatological procedures. Its development pipeline features CTX-101, a Phase III topical corticosteroid formulation utilizing MMPE technology for treating plaque psoriasis, and CTX-102, a Phase I topical therapy leveraging MMPE for an unspecified skin condition. Furthermore, several pre-clinical dermatology products are in development, also based on MMPE technology, for various prescription skin disease treatments. In the non-prescription sector, Crescita offers a broad selection of skincare items. Under the Laboratoire Dr Renaud brand, it provides facial creams, cleansers, exfoliants, masks, serums, and suncare products aimed at addressing concerns such as aging, acne, rosacea, pigmentation, dehydration, and sensitivity. The Pro-Derm line consists of dermocosmetic solutions specifically formulated for anti-aging medical procedures, while the Alyria brand targets a diverse range of skincare issues. Products under the Dermazulene brand are primarily intended for Asian consumers. The company also markets NCTF 135 HA, a skin revitalization solution focused on improving skin quality and reducing fine lines. Crescita has established key collaborations, including a development and licensing agreement with Sundial Growers Inc. for cannabis product development, a commercialization license agreement with Cantabria Labs Inc., and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was founded in 2016 and maintains its corporate headquarters in Laval, Canada.